Clinical Trials

41. DIA And CRO Leadership Awards Go Virtual 7/1/2020

    The team behind DIA’s Annual Meeting was able to put together an event that was as informative and engaging as past years, despite the short and very hectic time frame. More than 200 sessions took place virtually, with 120 of those being on demand.

42. 5 Bad Habits The Clinical Trial Community Needs To Break ASAP 7/1/2020

    I won’t attempt to address or solve all of the problems that contribute to the high cost of clinical trials, but I will highlight some continuing root causes that I believe persist needlessly.

43. 3 Essential Considerations For Running Global Clinical Trials 7/1/2020

    In this article we'll look at three key considerations when designing a global clinical trial: selecting the most appropriate trial sites with a representative patient population, choosing to work with the right partners, and ensuring you are up to speed with local regulatory and clinical requirements.

44. A Small Biopharma's View Of Working With CROs 7/1/2020

    Running a clinical-stage oncology biopharma with only five employees means you quickly learn a thing or two about the value of outsourcing services. For Pamela Contag, Ph.D., cofounder and CEO of BioEclipse Therapeutics, those learnings have led to her company using five CROs for the company’s lead investigational candidate.

45. Transformative Reflections On The Life Science World, Post-COVID-19 7/1/2020

    I’m reflecting on life after COVID-19, a couple years out — based on need and capacity to respond. While unorthodox, reflecting on a future possible outcome offers insight to the achievable and the opportunity to prepare for future clinical needs using current expertise and treatments.

46. A Small Biopharma That Doesn't Use CROs 12/30/2019

    When it comes to conducting clinical trials, most emerging companies choose to access external resources through partnering with CROs. That is what makes Martin Lehr, CEO of Context Therapeutics different. He prefers to bypass CROs and take part in Investigator-Sponsored Trials (ISTs).

47. Biotechs Will Make Music In The “Twenty-Twenties” 11/27/2019

    Outsourced Pharma Chief Editor Louis Garguilo talks with two biotech CEOs about why they believe this industry should expect an infusion of technology and improved productivity in the coming years.

48. Patient Diversity Starts With Community Connections 8/30/2019

    When it comes to clinical trials, the pharmaceutical industry still has a patient diversity problem. The face of patients in clinical trials is not representative of the face of America.

49. Comparative Biosimilar Clinical Trials: More Questions Than Answers? 8/30/2019

    As one expert said, though there are many reasons to praise clinical trials for their contributions to drug development, they may not always be the best method to answer some of the most important biosimilar questions we have today.

50. The Importance Of Pursuing Clinical Trial Costs 8/1/2019

    As clinical trials become more complex in terms of regulatory compliance and scope of study, it is more important than ever that procurement teams develop a clear understanding of the various cost drivers related to operating a clinical trial.